FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2072668090> ?p ?o ?g. }

• W2072668090 endingPage "1308" @default.
• W2072668090 startingPage "1303" @default.
• W2072668090 abstract "We investigated the possibility of DYRK2, a dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase gene, to predict survival for patients with pulmonary adenocarcinoma.One hundred forty-four patients with pulmonary adenocarcinoma underwent surgery in our institute from 2000 to 2008. We used immunohistochemical analysis and real-time reverse-transcriptase polymerase chain reaction to determine the expression of DYRK2 and compared this with the clinicopathologic factors and survival.We found no correlation between DYRK2 expression by immunohistochemical and clinicopathologic factors; however, a negative nodal status and negative lymphatic invasion were significantly associated with DYRK2 expression by reverse-transcriptase polymerase chain reaction. Five-year disease-free survival in the DYRK2-positive group (75.4%) was significantly different from that in the negative group (55.4%; P = .03) by immunohistochemical analysis. The 5-year overall survival of 89.2% in the DYRK2-positive group was better than the 66.3% survival of the DYRK2-negative group (P = .01). Quantitative real-time reverse-transcriptase polymerase chain reaction analyses showed a significant difference between positive and negative expressions for disease-free survival (P = .003) and overall survival (P = .007). In multivariate Cox regression analysis, negative DYRK2 protein and messenger RNA expression showed a worse prognostic value of survival (hazard ratio [HR] = 4.7, 95% confidence intervals [CI] = 1.5-14.5, P=.007; HR = 2.5, 95% CI = 1.1-6.1, P = .04, respectively). When we analyzed adenocarcinoma cases except for bronchioloalveolar carcinoma, we found a close correlation between DYRK2 expression by immunohistochemical analysis and nodal status (P = .03). Furthermore, disease-free survivals between positive and negative groups of DYRK2 expression by immunohistochemistry (P = .03) and reverse-transcriptase polymerase chain reaction (P = .02) without bronchioloalveolar carcinoma were significantly different. Overall survivals in both groups showed significant differences by immunohistochemistry (P = .02) but not by reverse-transcriptase polymerase chain reaction (P = .08).These data showed that DYRK2 expression is associated with a favorable prognosis." @default.
• W2072668090 created "2016-06-24" @default.
• W2072668090 creator A5008772830 @default.
• W2072668090 creator A5016281640 @default.
• W2072668090 creator A5029553820 @default.
• W2072668090 creator A5033485126 @default.
• W2072668090 creator A5063456684 @default.
• W2072668090 creator A5084608073 @default.
• W2072668090 creator A5090297788 @default.
• W2072668090 date "2009-12-01" @default.
• W2072668090 modified "2023-10-12" @default.
• W2072668090 title "Expression of dual-specificity tyrosine-(Y)-phosphorylation–regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma" @default.
• W2072668090 cites W1993312546 @default.
• W2072668090 cites W2016526701 @default.
• W2072668090 cites W2024202767 @default.
• W2072668090 cites W2064076505 @default.
• W2072668090 cites W2064840560 @default.
• W2072668090 cites W2077229666 @default.
• W2072668090 cites W2079552906 @default.
• W2072668090 cites W2105902643 @default.
• W2072668090 cites W2121110745 @default.
• W2072668090 doi "https://doi.org/10.1016/j.jtcvs.2009.08.003" @default.
• W2072668090 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19818968" @default.
• W2072668090 hasPublicationYear "2009" @default.
• W2072668090 type Work @default.
• W2072668090 sameAs 2072668090 @default.
• W2072668090 citedByCount "14" @default.
• W2072668090 countsByYear W20726680902013 @default.
• W2072668090 countsByYear W20726680902014 @default.
• W2072668090 countsByYear W20726680902016 @default.
• W2072668090 countsByYear W20726680902017 @default.
• W2072668090 countsByYear W20726680902019 @default.
• W2072668090 countsByYear W20726680902020 @default.
• W2072668090 countsByYear W20726680902021 @default.
• W2072668090 countsByYear W20726680902022 @default.
• W2072668090 countsByYear W20726680902023 @default.
• W2072668090 crossrefType "journal-article" @default.
• W2072668090 hasAuthorship W2072668090A5008772830 @default.
• W2072668090 hasAuthorship W2072668090A5016281640 @default.
• W2072668090 hasAuthorship W2072668090A5029553820 @default.
• W2072668090 hasAuthorship W2072668090A5033485126 @default.
• W2072668090 hasAuthorship W2072668090A5063456684 @default.
• W2072668090 hasAuthorship W2072668090A5084608073 @default.
• W2072668090 hasAuthorship W2072668090A5090297788 @default.
• W2072668090 hasBestOaLocation W20726680901 @default.
• W2072668090 hasConcept C104317684 @default.
• W2072668090 hasConcept C10515644 @default.
• W2072668090 hasConcept C121608353 @default.
• W2072668090 hasConcept C126322002 @default.
• W2072668090 hasConcept C143998085 @default.
• W2072668090 hasConcept C204232928 @default.
• W2072668090 hasConcept C207103383 @default.
• W2072668090 hasConcept C2781182431 @default.
• W2072668090 hasConcept C44249647 @default.
• W2072668090 hasConcept C48023723 @default.
• W2072668090 hasConcept C502942594 @default.
• W2072668090 hasConcept C50382708 @default.
• W2072668090 hasConcept C55493867 @default.
• W2072668090 hasConcept C71924100 @default.
• W2072668090 hasConcept C86803240 @default.
• W2072668090 hasConceptScore W2072668090C104317684 @default.
• W2072668090 hasConceptScore W2072668090C10515644 @default.
• W2072668090 hasConceptScore W2072668090C121608353 @default.
• W2072668090 hasConceptScore W2072668090C126322002 @default.
• W2072668090 hasConceptScore W2072668090C143998085 @default.
• W2072668090 hasConceptScore W2072668090C204232928 @default.
• W2072668090 hasConceptScore W2072668090C207103383 @default.
• W2072668090 hasConceptScore W2072668090C2781182431 @default.
• W2072668090 hasConceptScore W2072668090C44249647 @default.
• W2072668090 hasConceptScore W2072668090C48023723 @default.
• W2072668090 hasConceptScore W2072668090C502942594 @default.
• W2072668090 hasConceptScore W2072668090C50382708 @default.
• W2072668090 hasConceptScore W2072668090C55493867 @default.
• W2072668090 hasConceptScore W2072668090C71924100 @default.
• W2072668090 hasConceptScore W2072668090C86803240 @default.
• W2072668090 hasIssue "6" @default.
• W2072668090 hasLocation W20726680901 @default.
• W2072668090 hasLocation W20726680902 @default.
• W2072668090 hasOpenAccess W2072668090 @default.
• W2072668090 hasPrimaryLocation W20726680901 @default.
• W2072668090 hasRelatedWork W2010631330 @default.
• W2072668090 hasRelatedWork W2026784993 @default.
• W2072668090 hasRelatedWork W2581226876 @default.
• W2072668090 hasRelatedWork W2994686985 @default.
• W2072668090 hasRelatedWork W3136232645 @default.
• W2072668090 hasRelatedWork W4225134093 @default.
• W2072668090 hasRelatedWork W4281722959 @default.
• W2072668090 hasRelatedWork W4379796428 @default.
• W2072668090 hasRelatedWork W4380269519 @default.
• W2072668090 hasRelatedWork W4380448775 @default.
• W2072668090 hasVolume "138" @default.
• W2072668090 isParatext "false" @default.
• W2072668090 isRetracted "false" @default.
• W2072668090 magId "2072668090" @default.
• W2072668090 workType "article" @default.